Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Zymeworks BC Inc (NASDAQ: ZYME) closed at $16.26 in the last session, down -5.52% from day before closing price of $17.21. In other words, the price has decreased by -$5.52 from its previous closing price. On the day, 0.38 million shares were traded. ZYME stock price reached its highest trading level at $17.37 during the session, while it also had its lowest trading level at $16.21.
Ratios:
We take a closer look at ZYME’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.10 and its Current Ratio is at 4.10. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on November 07, 2024, Upgraded its rating to Outperform and sets its target price to $25 from $10 previously.
On November 01, 2024, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $12.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 05 ’24 when Galbraith Kenneth sold 18,198 shares for $10.65 per share. The transaction valued at 193,849 led to the insider holds 29,468 shares of the business.
Galbraith Kenneth sold 5,706 shares of ZYME for $63,996 on Jan 08 ’24. The Chair & CEO now owns 23,762 shares after completing the transaction at $11.22 per share. On Jan 05 ’24, another insider, Astle Christopher, who serves as the SVP & Chief Financial Officer of the company, sold 4,563 shares for $10.65 each. As a result, the insider received 48,606 and left with 7,934 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 1119948288 and an Enterprise Value of 843026560. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.15 while its Price-to-Book (P/B) ratio in mrq is 3.11. Its current Enterprise Value per Revenue stands at 13.554 whereas that against EBITDA is -7.349.
Stock Price History:
Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.42. The 50-Day Moving Average of the stock is 21.08%, while the 200-Day Moving Average is calculated to be 49.65%.
Shares Statistics:
According to the various share statistics, ZYME traded on average about 633.81K shares per day over the past 3-months and 711560 shares per day over the past 10 days. A total of 70.12M shares are outstanding, with a floating share count of 68.03M. Insiders hold about 2.05% of the company’s shares, while institutions hold 98.13% stake in the company. Shares short for ZYME as of 1730332800 were 4700126 with a Short Ratio of 7.42, compared to 1727654400 on 4049768. Therefore, it implies a Short% of Shares Outstanding of 4700126 and a Short% of Float of 8.41.
